

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptanscl625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * *

STN maintenance downtime to be extended

The normal maintenance downtime for STN will be extended on December 15. STN will be unavailable beginning Saturday, December 15, at 17:00 U.S. Eastern Standard Time until Sunday, December 16, at 01:00.

The normal schedule for STN maintenance downtime (22:00 to 01:00) will resume on December 22.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:30:17 ON 15 DEC 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:30:29 ON 15 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2007 HIGHEST RN 958257-59-5

DICTIONARY FILE UPDATES: 14 DEC 2007 HIGHEST RN 958257-59-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10890829DEC07.str



chain nodes :

7 8 9 16 17 18 19 20 21 22 23

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

2-16 3-18 4-22 5-21 6-7 7-8 7-19 8-9 8-23 9-10 9-20 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

2-16 6-7 7-8 8-9 8-23 9-10 16-17

exact bonds :

3-18 4-22 5-21 7-19 9-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss l1 sam
SAMPLE SEARCH INITIATED 11:30:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d scan

L2 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[3-(
pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4S)- (9CI)
MF C20 H25 F N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s sss l1 full
FULL SEARCH INITIATED 11:31:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 235 TO ITERATE

100.0% PROCESSED 235 ITERATIONS 114 ANSWERS
SEARCH TIME: 00.00.01

L3 114 SEA SSS FUL L1

=> save temp l3 Morgl0890829/A
'MORG10890829/A' IN USE

A single name cannot be used for two saved items at the same time.
Enter "Y" if you wish to replace the current saved name with a new
definition. Enter "N" if the current saved definition must be
preserved. You may then reenter the SAVE command with a different
saved name. Enter "DISPLAY SAVED" at an arrow prompt (=>) to see a
list of your currently defined saved names.

REPLACE OLD DEFINITION? Y/(N):y
ANSWER SET L3 HAS BEEN SAVED AS 'MORG10890829/A'

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.00	173.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:32:11 ON 15 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 14 Dec 2007 (20071214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



=> s 13

L4 4 L3

=> d ibib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:333017 CAPLUS Full-text
DOCUMENT NUMBER: 146:358713
TITLE: Preparation of (hetero)aryllureas as modulators of the cardiac sarcomere for treatment of heart failure.
INVENTOR(S): Morgan, Bradley P.; Muci, Alex; Kraynack, Erica; Lu, Pu-Ping; Tochimoto, Todd; Morgans, David J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 38pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2007066626	A1	20070322	US 2006-498986	20060804
PRIORITY APPLN. INFO.:			US 2005-705848P	P 20050804
			US 2005-751123P	P 20051216
OTHER SOURCE(S):	MARPAT	146:358713		
GI				



AB Title compds. [I; W, X, Y, Z = C, N; ≤2 of W, X, Y, Z = N; R1 = (substituted) alkyl, amino, aryl, heteroaryl, heterocycloalkyl; R2 = (substituted) aryl, aralkyl, cycloalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl; R3-R5 = null, H, halo, cyano, NO2, (substituted) alkyl, heterocycloalkyl, heteroaryl; R6, R7 = H, (substituted) alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl; R13 = null, H, halo, cyano, NO2, OH, (substituted) alkyl, heterocycloalkyl, heteroaryl; with provisos], were prepared as modulators of the cardiac sarcomere for treatment of heart failure (no data). Thus, title compound (II) was prepared from 1,3-diaminopropan-2-ol, MeI, 3,5-difluoronitrobenzene, SO2Cl2, and 3-isocyanatopyridine.

IT 929873-54-1P 929873-55-2P 929873-56-3P

929873-57-4P 929873-58-5P 929873-59-6P

929873-63-2P 929873-64-3P 929873-67-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of (hetero)arylureas as modulators of the cardiac sarcomere for treatment of heart failure)

RN 929873-54-1 CAPLUS

CN Urea, N-[3-fluoro-5-[[[(3aS,5R)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 929873-55-2 CAPLUS

CN Urea, N-[3-fluoro-5-[[[(3aS,5S)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 929873-56-3 CAPLUS

CN Urea, N-[3-fluoro-5-[(3aR,5R)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 929873-57-4 CAPLUS

CN Urea, N-[3-fluoro-5-[(3aS,5R)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929873-58-5 CAPLUS

CN Urea, N-[3-fluoro-5-[(3aR,4S)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-4-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 929873-59-6 CAPLUS


CN Urea, N-[3-fluoro-5-[(3aR,4S)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-4-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929873-63-2 CAPLUS

CN Urea, N-[3-fluoro-5-[(tetrahydro-2,6-dimethyl-1,1-dioxido-2H-1,2,6-thiadiazin-4-yl)oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)



RN 929873-64-3 CAPLUS


CN Urea, N-[3-fluoro-5-[(tetrahydro-2,6-dimethyl-1,1-dioxido-2H-1,2,6-thiadiazin-4-yl)oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 929873-67-6 CAPLUS

CN Urea, N-[3-fluoro-5-[(3aR,5R)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:103197 CAPLUS Full-text
 DOCUMENT NUMBER: 144:192115
 TITLE: Process for preparation of N-phenylureas
 INVENTOR(S): Morgan, Bradley Paul; Yiannikouros, George Petros;
 Cruskie, Michael P.; Goss, Christopher Roy
 PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006025470	A1	20060202	US 2005-32227	20050111
US 7176222	B2	20070213		

PRIORITY APPLN. INFO.:
 US 2004-591338P P 20040727
 US 2004-591525P P 20040727
 US 2004-616341P P 20041005

OTHER SOURCE(S): CASREACT 144:192115; MARPAT 144:192115
 GI



AB A process for N-phenylureas (I) (R = H, halo, optionally substituted heteroaryl, nitro; R2 = each optionally substituted aryl, aralkyl, cycloalkyl, heteroaryl, heteroaralkyl, or heterocyclyl; R3 = each optionally substituted acyl or alkoxy carbonyl, amidino, sulfonyl; n = 1, 2) comprises at least one of the steps: (A) contacting a base with an enantiomerically pure pyrrolidin-3-ol or piperidine-3-ol derivative (II) (R3, n = same as above) and (B) reacting the product of step A with a 2-fluoronitrobenzene derivative (III) for etherification, and (C) converting the product of step B (IV) to the compound I. These compds. selectively modulate the cardiac sarcomere for the treatment for systolic heart failure, including congestive heart failure. Thus, a

solution of 1.22 kg 1-((R)-3-Hydroxypiperidin-1-yl)ethanone and 0.029 kg imidazole in 2.43 L N-methylpyrrolidone was added dropwise to a mixture 0.442 kg NaH and 4.86 L N-methylpyrrolidone (precooled at 0±5°) over 1.5 h maintaining the internal temperature at 5±5° in a ice/brine bath, followed by adding a solution of 2.70 kg 3,5-difluoronitrobenzene in 2.43 L N-methylpyrrolidone over 2 h maintaining internal temperature at 10±5°, and the resulting mixture was heated to 70±5° for 11 h to give, after workup, a mixture of 83.2% 1-[(R)-3-(3-fluoro-5- nitrophenoxy)piperidin-1-yl]ethanone and 9.2% 1-[(R)-3-(3,5- Difluorophenoxy)piperidin-1-yl]ethanone in 95% yield (4.79 kg). A solution of the above mixture (4.54 kg) in 13.6 L MeOH was added to a mixture of 0.454 kg 10% Pd-C and 13.62 L MeOH, followed by 4.54 L MeOH, and the resulting mixture was heated to a gentle reflux and treated dropwise with a solution of 5.07 kg ammonium formate in 3.63 L H2O over 10 h to give, after workup, 3.06 kg 1-[(R)-3-(3-amino-5-fluorophenoxy)piperidin-1-yl]ethanone (95.4% ee) in 75% yield which was converted into 1-[(R)-3-(3-amino-5- fluorophenoxy)piperidin-1-yl]ethanone hydrochloride (V). A solution of 1.441 kg V in 14.4 L CH2Cl2 was treated with 0.710 kg diisopropylethylamine, cooled to 10±5° in an ice/brine bath, treated with 0.659 kg 3-isocyanatopyridine, warmed to room temperature, and stirred for 3 h to give, after workup, crystallization, and trituration with H2O, 61% (R)-N-[3-[(1- acetylpiperidin-3-yl)oxy]-5-fluorophenyl]-N'-(pyridin-3-yl)urea (3.74 kg, 99.2% purity).


IT 732245-95-3P, (R)-N-[3-[(1-Acetylpiperidin-3-yl)oxy]-5-fluorophenyl]-N'-(pyridin-3-yl)urea 732246-49-0P, (R)-3-[3-Fluoro-5-[N'-(pyridin-3-yl)ureido]phenoxy]pyrrolidine-1-sulfonic acid dimethylamide
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of N-phenylureas modulating cardiac sarcomere by etherification of pyrrolidin-3-ol or piperidine-3-ol derivative with 2-fluoronitrobenzene derivative)

RN 732245-95-3 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[3-(pyridin-3-ylamino)carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-49-0 CAPLUS

CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[3-(pyridin-3-ylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:641873 CAPLUS Full-text

DOCUMENT NUMBER: 143:153299

TITLE: Preparation of substituted urea derivatives for use in treating heart failure

INVENTOR(S): Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-Ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of Appl. No. PCT/US04/001069.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005159416	A1	20050721	US 2004-890829	20040714
WO 2004064730	A2	20040805	WO 2004-US1069	20040114
WO 2004064730	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

PRIORITY APPLN. INFO.:
 US 2003-440133P P 20030114
 US 2003-440183P P 20030114
 US 2003-476086P P 20030604
 US 2003-476517P P 20030605
 US 2003-501376P P 20030908
 WO 2004-US1069 A2 20040114

OTHER SOURCE(S): MARPAT 143:153299

AB The present invention provides substituted urea derivs., pharmaceutical compns. containing the derivs., and methods for the treatment of heart failure including congestive heart failure, particularly systolic heart failure. The compns. are selective modulators of the cardiac sarcomere, for example, potentiating cardiac myosin. The ureas of the invention are represented by the formula R1NHC(O)NHR2 wherein: R1 is optionally substituted aryl or heteroaryl; and R2 is optionally substituted aryl, aralkyl; cycloalkyl, heteroaryl, heteroaralkyl or heterocyclyl, including single stereoisomers, mixts. of stereoisomers, and the pharmaceutically acceptable salts, solvates, and solvates of pharmaceutically acceptable salts thereof.

IT 732246-14-9P, N-[3-(1-Acetyl piperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methoxypyridin-3-yl)urea 732246-15-0P, N-[3-(1-

Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(pyridin-3-yl)urea
 732246-16-1P, N-[3-Fluoro-5-(1-(methylsulfonyl)piperidin-3-
 yloxy)phenyl]-N'-(pyridin-3-yl)urea 732246-17-2P
 732246-18-3P, (R)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-
 N'-(6-methoxypyridin-3-yl)urea 732246-19-4P,
 (R)-3-[3-Fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-1-
 piperidinecarboxylic acid methyl ester 732246-20-7P
 732246-21-8P, (R)-N-[3-Fluoro-5-(1-(methylsulfonyl)piperidin-3-
 yloxy)phenyl]-N'-(pyridin-3-yl)urea 732246-22-9P,
 (R)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methylpyridin-3-
 yl)urea 732246-23-0P 732246-24-1P 732246-25-2P
 , (R)-N-[3-Fluoro-5-(1-(methylsulfonyl)piperidin-3-yloxy)phenyl]-N'-(6-
 methylpyridin-3-yl)urea 732246-26-3P 732246-27-4P
 732246-28-5P 732246-29-6P, (R)-N-[3-Fluoro-5-[[1-(propan-
 2-ylsulfonyl)piperidin-3-yl]oxy]phenyl]-N'-(pyridin-3-yl)urea
 732246-30-9P, (R)-N-[3-Fluoro-5-[[1-(propan-2-ylsulfonyl)piperidin-
 3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea 732246-31-0P,
 (R)-N-[3-(1-(Ethylsulfonyl)piperidin-3-yloxy)-5-fluorophenyl]-N'-(pyridin-
 3-yl)urea 732246-32-1P 732246-33-2P
 732246-34-3P 732246-35-4P 732246-36-5P
 732246-37-6P, (S)-N-[3-(1-(Ethylsulfonyl)piperidin-3-yloxy)-5-
 fluorophenyl]-N'-(pyridin-3-yl)urea 732246-38-7P,
 (S)-N-[3-Fluoro-5-[[1-(propan-2-ylsulfonyl)piperidin-3-yl]oxy]phenyl]-N'-(
 pyridin-3-yl)urea 732246-39-8P 732246-40-1P 7322
 46-41-2P, (S)-N-[3-Fluoro-5-[[1-(propan-2-ylsulfonyl)piperidin-3-
 yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea 732246-42-3P
 732246-43-4P, (S)-N-[3-Fluoro-5-(1-(methylsulfonyl)piperidin-3-
 yloxy)phenyl]-N'-(pyridin-3-yl)urea 732246-44-5P
 732246-45-6P 732246-46-7P 732246-47-8P
 732246-49-0P 732246-51-4P 732246-52-5P
 732246-53-6P 732246-54-7P 732246-55-8P,
 (S)-N-[3-Fluoro-5-[[1-(propan-2-ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(
 pyridin-3-yl)urea 732246-56-9P, (S)-N-[3-Fluoro-5-[[1-(propan-2-
 ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea
 732246-57-0P, (S)-N-[3-Fluoro-5-[[1-(ethan-2-ylsulfonyl)pyrrolidin-
 3-yl]oxy]phenyl]-N'-(pyridin-3-yl)urea 732246-58-1P,
 (S)-N-[3-Fluoro-5-[[1-(ethan-2-ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(
 6-methylpyridin-3-yl)urea 732246-59-2P, (R)-N-[3-Fluoro-5-[[1-
 (ethan-2-ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-
 yl)urea 732246-60-5P, (S)-N-[3-Fluoro-5-[[1-
 (methylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea
 732246-61-6P, (R)-N-[3-Fluoro-5-[[1-(propan-2-
 ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea
 732246-62-7P 732246-63-8P 732246-64-9P
 732246-65-0P 732246-66-1P 732246-67-2P
 732246-68-3P 859838-51-0P, (S)-N-[3-(1-Acetylpiperidin-3-
 yloxy)-5-fluorophenyl]-N'-(6-methoxypyridin-3-yl)urea 859838-52-1P
 , (S)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(pyridin-3-
 yl)urea 859838-53-2P 859838-55-4P,
 (S)-N-[3-(1-Acetylpiperidin-3-yloxy)-5-fluorophenyl]-N'-(6-methylpyridin-3-
 yl)urea 859838-60-1P 859838-63-4P,
 (S)-N-[3-Fluoro-5-(1-(methylsulfonyl)piperidin-3-yloxy)phenyl]-N'-(6-
 methylpyridin-3-yl)urea 859838-79-2P 859838-82-7P
 859838-87-2P 859838-90-7P 859838-92-9P
 859838-98-5P 859839-00-2P 859839-02-4P
 859839-03-5P 859839-04-6P 859839-05-7P
 859839-06-8P 859839-07-9P 859839-08-0P
 859839-09-1P 859839-10-4P 859839-11-5P,
 (R)-N-[3-Fluoro-5-[[1-(propan-2-ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(
 pyridin-3-yl)urea 859839-12-6P, (R)-N-[3-Fluoro-5-[[1-(ethan-2-

ylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(pyridin-3-yl)urea
 859839-13-7P, (R)-N-[3-Fluoro-5-[[1-(methylsulfonyl)pyrrolidin-3-yl]oxy]phenyl]-N'-(6-methylpyridin-3-yl)urea 859839-14-8P
 859839-15-9P 859839-16-0P 859839-19-3P
 859839-22-8P 859839-24-0P 859839-26-2P
 859839-28-4P 859839-30-8P 859839-32-0P
 859839-33-1P 859839-34-2P 859839-35-3P
 859839-36-4P 859839-37-5P 859839-38-6P
 859839-39-7P 859839-40-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted urea derivs. for use in treating

heart failure)


RN 732246-14-9 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 732246-15-0 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 732246-16-1 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 732246-17-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 732246-18-3 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-19-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[3-(pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-20-7 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[3-(pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-21-8 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-22-9 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-23-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-24-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-25-2 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[3-(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-26-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-(3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-27-4 CAPLUS


CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[3-(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-28-5 CAPLUS
CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-29-6 CAPLUS
CN Piperidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-30-9 CAPLUS
CN Piperidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 732246-31-0 CAPLUS
CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-32-1 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-33-2 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 732246-34-3 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 732246-35-4 CAPLUS

CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino] phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-36-5 CAPLUS

CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-37-6 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-38-7 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-39-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-40-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-41-2 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[6-methyl-3-pyridinyl]amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-42-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-43-4 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-44-5 CAPLUS


CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-45-6 CAPLUS
CN 1-Pyrrolidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 732246-46-7 CAPLUS
CN 1-Pyrrolidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 732246-47-8 CAPLUS
CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 732246-49-0 CAPLUS
CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-51-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-52-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-53-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-54-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-55-8 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-56-9 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-57-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-58-1 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-59-2 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-60-5 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-61-6 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-62-7 CAPLUS

CN 1-Pyrrolidinesulfonamide, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-63-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, methyl ester, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-64-9 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-65-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[3-(3-methylpyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 732246-66-1 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 732246-67-2 CAPLUS


CN Urea, N-[3-fluoro-5-[[6S,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-68-3 CAPLUS
CN Urea, N-[3-fluoro-5-[[(6S,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 859838-51-0 CAPLUS
CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859838-52-1 CAPLUS
CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859838-53-2 CAPLUS
CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-55-4 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-60-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-63-4 CAPLUS


CN Piperidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859838-79-2 CAPLUS
 CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino] phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 859838-82-7 CAPLUS
 CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl) amino] carbonyl] amino] phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 859838-87-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl) amino] carbonyl] amino] phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859838-90-7 CAPLUS
 CN Urea, N-[3-fluoro-5-[[(5R)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl] oxy] phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-92-9 CAPLUS

CN Urea, N-[3-fluoro-5-[[(5S)-hexahydro-2-methyl-1,1-dioxidopyrrolo[1,2-b][1,2,5]thiadiazol-5-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859838-98-5 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-00-2 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-02-4 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-03-5 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-04-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, methyl ester, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-05-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, methyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-06-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, methyl ester, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-07-9 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-08-0 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry..



RN 859839-09-1 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-10-4 CAPLUS

CN Pyrrolidine, 1-acetyl-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-11-5 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-12-6 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-13-7 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-14-8 CAPLUS

CN 1-Pyrrolidinesulfonamide, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-N,N-dimethyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-15-9 CAPLUS

CN 1-Pyrrolidinesulfonamide, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-N,N-dimethyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-16-0 CAPLUS

CN 1-Pyrrolidinesulfonamide, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-19-3 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, (3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-22-8 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-24-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-26-2 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[3-(pyridinylamino) carbonyl] amino]phenoxy]-2-(methoxymethyl)-, (2S,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-28-4 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[3-(pyridinylamino) carbonyl] amino]phenoxy]-2-(methoxymethyl)-, (2R,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-30-8 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[3-(pyridinylamino) carbonyl] amino]phenoxy]-2-(methoxymethyl)-, (2R,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-32-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-33-1 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-34-2 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2R,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 859839-35-3 CAPLUS

CN Urea, N-[3-fluoro-5-[[(6S,7aS)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-36-4 CAPLUS

CN Urea, N-[3-fluoro-5-[[(6R,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-37-5 CAPLUS

CN Urea, N-[3-fluoro-5-[[(6R,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-38-6 CAPLUS

CN Urea, N-[3-fluoro-5-[[(6S,7aS)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-39-7 CAPLUS

CN Urea, N-[3-fluoro-5-[(6R,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859839-40-0 CAPLUS

CN Urea, N-[3-fluoro-5-[(6R,7aS)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 732245-95-3P 732245-96-4P 732246-02-5P

732246-03-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted urea derivs. for use in treating heart failure)

RN 732245-95-3 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[(3-pyridinylamino)carbonylamino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732245-96-4 CAPLUS

CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-02-5 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-03-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 732246-00-3P 732246-01-4P 732246-06-9P

732246-07-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted urea derivs. for use in treating heart failure)

RN 732246-00-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-01-4 CAPLUS

CN Urea, N-[3-fluoro-5-[(3R)-3-pyrrolidinyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-06-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-07-0 CAPLUS

CN Urea, N-[3-fluoro-5-[(3S)-3-piperidinyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:633440 CAPLUS Full-text

DOCUMENT NUMBER: 141:167784

TITLE: Compositions and methods to treat heart failure

INVENTOR(S): Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J., Jr.

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064730	A2	20040805	WO 2004-US1069	20040114
WO 2004064730	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
AU 2004206860	A1	20040805	AU 2004-206860	20040114
CA 2511970	A1	20040805	CA 2004-2511970	20040114
EP 1615878	A2	20060118	EP 2004-702228	20040114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1738793	A	20060222	CN 2004-80002177	20040114
JP 2006515884	T	20060608	JP 2006-500973	20040114
US 2005159416	A1	20050721	US 2004-890829	20040714
MX 2005PA07513	A	20050921	MX 2005-PA7513	20050713
IN 2005DN03136	A	20070302	IN 2005-DN3136	20050714
US 2006241110	A1	20061026	US 2006-541596	20060425
PRIORITY APPLN. INFO.:			US 2003-440133P	P 20030114
			US 2003-440183P	P 20030114
			US 2003-476086P	P 20030604
			US 2003-476517P	P 20030605
			US 2003-501376P	P 20030908
			WO 2004-US1069	W 20040114

OTHER SOURCE(S): MARPAT 141:167784

AB Certain substituted urea derivs. selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

IT 732245-95-3P 732245-96-4P 732246-02-5P

732246-03-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(compds. to treat congestive heart failure)

RN 732245-95-3 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732245-96-4 CAPLUS

CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-02-5 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-03-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 732246-14-9 732246-15-0 732246-16-1
 732246-17-2 732246-18-3 732246-19-4
 732246-20-7 732246-21-8 732246-22-9
 732246-23-0 732246-24-1 732246-25-2
 732246-26-3 732246-27-4 732246-28-5
 732246-29-6 732246-30-9 732246-31-0
 732246-32-1 732246-33-2 732246-34-3
 732246-35-4 732246-36-5 732246-37-6
 732246-38-7 732246-39-8 732246-40-1
 732246-41-2 732246-42-3 732246-43-4
 732246-44-5 732246-45-6 732246-46-7
 732246-47-8 732246-49-0 732246-51-4
 732246-52-5 732246-53-6 732246-54-7
 732246-55-8 732246-56-9 732246-57-0
 732246-58-1 732246-59-2 732246-60-5
 732246-61-6 732246-62-7 732246-63-8
 732246-64-9 732246-65-0 732246-66-1
 732246-67-2 732246-68-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (comps. to treat congestive heart failure)


RN 732246-14-9 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 732246-15-0 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 732246-16-1 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 732246-17-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



RN 732246-18-3 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methoxy-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-19-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-20-7 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-21-8 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-22-9 CAPLUS

CN Piperidine, 1-acetyl-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-23-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-24-1 CAPLUS

CN 1-Piperidinecarboxamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-25-2 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-26-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-27-4 CAPLUS

CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino] phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-28-5 CAPLUS

CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl) amino] carbonyl] amino] phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-29-6 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[(3-pyridinylamino) carbonyl] amino] phenoxy]-1-[(1-methylethyl) sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-30-9 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl) amino] carbonyl] amino] phenoxy]-1-[(1-methylethyl) sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-31-0 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-32-1 CAPLUS

CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[6-methyl-3-pyridinyl]amino]carbonyl]amino]phenoxy]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-33-2 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[3-(pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 732246-34-3 CAPLUS
CN 1-Piperidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 732246-35-4 CAPLUS
CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-36-5 CAPLUS
CN 1-Piperidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 732246-37-6 CAPLUS
CN Piperidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-38-7 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-39-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-40-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-41-2 CAPLUS

CN Piperidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-42-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-43-4 CAPLUS


CN Piperidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-44-5 CAPLUS
 CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-45-6 CAPLUS
 CN 1-Pyrrolidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 732246-46-7 CAPLUS
 CN 1-Pyrrolidinecarboximidamide, N'-cyano-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 732246-47-8 CAPLUS
 CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-49-0 CAPLUS

CN 1-Pyrrolidinesulfonamide, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-N,N-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-51-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-52-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-53-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-54-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-55-8 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-56-9 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-57-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[3-(6-methyl-3-pyridinylamino)carbonyl]amino]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-58-1 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[3-(6-methyl-3-pyridinylamino)carbonyl]amino]phenoxy]pyrrolidin-1-yl]propane-1-sulfonamide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-59-2 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[3-(6-methyl-3-pyridinylamino)carbonyl]amino]phenoxy]pyrrolidin-1-yl]propane-1-sulfonamide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-60-5 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-61-6 CAPLUS

CN Pyrrolidine, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-1-[(1-methylethyl)sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-62-7 CAPLUS

CN 1-Pyrrolidinesulfonamide, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-63-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, methyl ester, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-64-9 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-4-methoxy-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-65-0 CAPLUS

CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[(3-pyridinylamino)carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-66-1 CAPLUS


CN Pyrrolidine, 1-(ethylsulfonyl)-4-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-2-(methoxymethyl)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-67-2 CAPLUS
 CN Urea, N-[3-fluoro-5-[[(6S,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 732246-68-3 CAPLUS
 CN Urea, N-[3-fluoro-5-[[(6S,7aR)-tetrahydro-3-oxo-1H,3H-pyrrolo[1,2-c]oxazol-6-yl]oxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 732246-00-3P 732246-01-4P 732246-06-9P
 732246-07-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (comps. to treat congestive heart failure)
 RN 732246-00-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 732246-01-4 CAPLUS
 CN Urea, N-[3-fluoro-5-[(3R)-3-pyrrolidininyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-06-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-fluoro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 732246-07-0 CAPLUS

CN Urea, N-[3-fluoro-5-[(3S)-3-piperidinyloxy]phenyl]-N'-(6-methyl-3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

=> logoff h

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
22.96	196.17

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-3.12	-3.12

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 11:34:51 ON 15 DEC 2007